Natera inc(NTRA.US AI Earnings Summary)
NTRA AI Earnings Summary (In-Depth)
2026 Q3
Core Highlights
- Stock Price Reaction: NATERA INC released its earnings report after the market closed on November 5, ET. Although revenue beat and full-year revenue guidance was raised, the net loss of $0.42 per share was wider than the -$0.28 market expectation and a CEO transition was announced; the stock closed at $310.67 on November 6, down 14.59% from the November 5 close of $363.76.
- Market Expectations: Q3 revenue reached $794M, approximately 12.2% higher than the market expectation of $708M. The primary reason for significantly exceeding expectations was strong demand for Minimal Residual Disease (MRD) clinical testing, which drove clinical MRD testing volume to approximately 316,000 units (up 56% YoY), along with an increase in Average Selling Price (ASP).
- Against Previous Guidance: Both Q3 revenue and gross margin met targets; full-year revenue guidance was raised to $3.005B–$3.035B, approximately 3.8% higher than the upper limit of the previous guidance of $2.91B; full-year gross margin guidance was maintained at 64%–66%. All performance metrics met or exceeded guidance.
- In One Sentence: Q3 revenue and Minimal Residual Disease (MRD) testing volume reached record highs, driving full-year revenue guidance to exceed $3B for the first time, yet the market responded with a 14.59% decline at the November 6 close.
Quarterly Highlights
Q3 2026 revenue was approximately 12.2% above market expectations, primarily driven by the dual engines of Signatera clinical volume and ASP.
Revenue significantly beat market expectations with strong organic growth momentum: Q3 2026 GAAP revenue reached $794M, up approximately 34% YoY, and was 12.2% higher than the TradingView pre-earnings market expectation of $707.5M. Excluding revenue true-ups (adjustments to revenue estimates for prior periods), organic growth exceeded 40%, indicating that core business momentum is far stronger than the headline numbers suggest.
Clinical MRD testing volume hit a record high with a clear accelerating YoY trend: Clinical Minimal Residual Disease (MRD) testing volume reached approximately 316,000 units this quarter, a 56% YoY increase compared to 202,000 units in the same period last year, and a sequential increase of 33,000 units. This marks the second consecutive quarter with a sequential increase of over 30,000 units. Measured by absolute YoY growth, this quarter added 113,000 units compared to the same period last year, showing continuous acceleration compared to previous quarters (63k, 73k, 81k, 88k, 102k).
Full-year revenue outlook significantly raised, breaking the $3B threshold for the first time: Management raised the 2026 full-year GAAP revenue guidance from the previous range of $2.85B–$2.91B to $3.005B–$3.035B. The midpoint was raised by approximately $140M, and the new range is 3.8% above the previous upper limit, marking the first time the company's full-year outlook has exceeded $3B.
Organic gross margin increased by 140 basis points QoQ, reflecting improved underlying execution: GAAP gross margin was approximately 64.7%. Excluding true-ups, organic gross margin was 63.2%, up approximately 140 basis points from 61.8% in Q2 2026. Driving factors include the continuous rise in Signatera Average Selling Price (ASP), laboratory economies of scale, and renegotiations with major suppliers.
Signatera ASP continues to climb with a clear long-term path: Signatera ASP reached approximately $1,290 this quarter, up again from approximately $1,271 in Q2 2026. Management reiterated a long-term ASP target of $2,000 and noted that reaching the 2029 revenue goal of $6B only requires the ASP to rise to approximately $1,450, leaving ample upside room.
Medicare adds Hepatocellular Carcinoma coverage; 9–10 MolDX pipeline items pending: Medicare approved Signatera for sequential monitoring in early-stage Hepatocellular Carcinoma (HCC) this quarter, affecting approximately 40,000 new US patients annually. CFO Michael Brophy pointed out that 9 to 10 MolDX indication applications are still under review, which remains the most important potential driver for Signatera ASP upside.
Biopharma partnership business sees explosive growth, exceeding full-year 2025 in the first three quarters: Biopharma partnership revenue reached $63M in the first three quarters of 2026, a 70% increase compared to $36M for the full year of 2025, and Q4 expectations remain strong. The IMvigor011 trial readout and companion diagnostic approval have opened the floodgates for market demand in MRD-guided clinical trials.
FIND early cancer screening study completes enrollment, receives FDA Breakthrough Device Designation: The FIND-CRC prospective screening study has completed enrollment of 30,000 patients, with results expected in 2027 to support an FDA application. Additionally, the Multi-Cancer Early Detection (MCED) test received FDA Breakthrough Device Designation in October 2026, providing a more collaborative and accelerated path for subsequent reviews.
Continuous positive cash inflows; net loss per share narrows significantly: The company achieved positive free cash flow again this quarter. Diluted net loss per share was $0.42, an improvement of $0.22 from $0.64 in the same period last year. Total cash, cash equivalents, and restricted cash reached $1.0972B at the end of the period, providing ample financial flexibility.